Biosimilar Humira Blocked Until 2023, But Time Could Clear Commercial Path

 
• By Jessica Merrill

Amgen settled patent infringement litigation with AbbVie, allowing its Humira biosimilar Amjevita to launch in Europe in October 2018, but blocking entry in the US until 2023. The deal could set a bar for other Humira biosimilar developers.

Patent Law Concept 3D Illustration

More from New Products

More from Scrip